IPO - Aptevo Therapeutics Inc.

Form Type: 424B4

Filing Date: 2025-06-20

Corporate Action: Ipo

Type: New

Accession Number: 000095017025088195

Filing Summary: Aptevo Therapeutics Inc. is publicly offering a registration of 2,105,000 shares of common stock along with 12,325,000 common warrants to purchase shares at an offering price of $3.25 per share. Additionally, 360,000 pre-funded warrants are being issued to certain purchasers, enabling them to acquire shares without exceeding 4.99% or 9.99% beneficial ownership thresholds. Each warrant comes with specific exercise prices and terms of expiration. The offering also highlights the significant clinical focus of Aptevo, detailing their ongoing development of bispecific immunotherapy candidates, particularly mipletamig for AML and ALG.APV-527 for solid tumors. The document outlines the growth strategies involving preclinical candidates and collaborative efforts for funding. The offering aims to raise capital while taking risks associated with market acceptance and operational success into account, providing a clear indication of the company’s plans moving forward in the biotech sector.

Form Type: S-1MEF

Filing Date: 2025-06-18

Corporate Action: Ipo

Type: New

Accession Number: 000095017025087813

Filing Summary: Aptevo Therapeutics Inc. filed an S-1MEF Registration Statement with the SEC for a public offering of additional securities. The filing follows a prior effective Registration Statement (No. 333-288061) also lodged by Aptevo on June 16, 2025, which was declared effective on June 18, 2025. The new filing registers an increase in the maximum aggregate offering price by $67,500, comprising $11,250 worth of common stock and prefunded warrants for purchasing $11,250 worth of common stock, in addition to common warrants to purchase up to $56,250 worth of common stock. This additional offering is limited to 20% of the maximum aggregate offering price set forth in the prior filing. The document also includes a commitment that the registration statement will become effective upon filing in accordance with Rule 462(b) of the Securities Act of 1933, along with necessary consents and opinions attached as exhibits.

Form Type: S-1

Filing Date: 2025-06-16

Corporate Action: Ipo

Type: New

Accession Number: 000095017025086548

Filing Summary: Aptevo Therapeutics Inc., a clinical-stage biotechnology company, is filing a registration statement under the Securities Act of 1933 for a public offering of securities including up to 1,709,401 shares of common stock, pre-funded warrants, and common warrants. The offering aims to raise funds for advancing their pipeline of novel bispecific immunotherapy candidates targeting various cancers, specifically focusing on two lead clinical candidates, mipletamig and ALG.APV-527. Mipletamig is currently undergoing evaluation in a Phase 1b/2 trial for acute myelogenous leukemia, while ALG.APV-527 is being tested for solid tumors. The registration also includes details about the underwriting agreement with Roth Capital Partners as the exclusive placement agent, emphasizing the urgency for obtaining required stockholder approvals for the exercise of the common warrants. The filing indicates a proposed offering price of $4.68 per share, though the actual price may vary based on market conditions. Aptevo states that there are significant risks involved, including the potential impact of market factors on their offering outcomes. The company has outlined extensive use of proceeds such as for clinical development, operational costs, and other general corporate purposes. The anticipated termination of this offering is no later than June 30, 2025. Investors are advised of the high degree of risk involved with investing in these securities, alongside ongoing regulatory requirements for Nasdaq listing compliance.

Form Type: DRS

Filing Date: 2025-05-30

Corporate Action: Ipo

Type: New

Accession Number: 000095012325005937

Filing Summary: Aptevo Therapeutics Inc. is filing a preliminary prospectus for a proposed public offering of up to 2,032,520 shares of common stock, alongside pre-funded warrants and common warrants, aimed at raising capital needed for the development and commercialization of its novel bispecific immunotherapy candidates. The document outlines the structure of the offering, including the pricing strategy, conditions for warrant exercise related to stockholder approval at Nasdaq, and potential risks that investors should consider. Notably, there is an emphasis on the company's focus on the treatment of various cancers using advanced biopharmaceutical approaches. The placement agent, Roth Capital Partners, LLC, is tasked with managing the offering without a minimum proceeds guarantee from investors, indicating a high-risk environment for potential investors.

Form Type: S-1

Filing Date: 2025-05-13

Corporate Action: Ipo

Type: New

Accession Number: 000095017025070551

Filing Summary: Aptevo Therapeutics Inc. filed a registration statement on Form S-1 with the SEC on May 13, 2025, for a public offering of up to 3,529,420 shares of its Common Stock. The shares are being registered for resale by certain stockholders who received the shares as part of a private placement alongside the issuance of common stock purchase warrants. The offering price for the shares, along with the associated warrants, was $1.19 per share. Aptevo’s Common Stock is traded on the Nasdaq Capital Market under the symbol 'APVO'. The company is a clinical-stage biotechnology firm focusing on developing immunotherapy candidates for cancer treatment, with two clinical candidates and several preclinical candidates currently in development. Aptevo plans to grow its business through advancing unique drug candidates employing their ADAPTIR and ADAPTIR-FLEX platforms, aimed at enhancing immune responses against cancer. The prospectus outlines the company's business overview, product pipeline, risk factors, and use of proceeds, although Aptevo will not receive any proceeds from the resale of the registered shares. This IPO indicates a significant step in Aptevo’s efforts to attract further investment and continue its research and clinical trials.

Form Type: 424B4

Filing Date: 2025-04-28

Corporate Action: Ipo

Type: New

Accession Number: 000095017025058974

Filing Summary: On April 28, 2025, Aptevo Therapeutics Inc. filed a prospectus supplement under Rule 424(b)(5) related to an At The Market Offering Agreement with Roth Capital Partners, allowing the company to sell shares of its common stock valued up to $50,000,000 over time. This offering is subject to market conditions, with Roth acting as the sales agent and earning a commission of 3.0% on the gross proceeds. As of the filing date, the aggregate market value of outstanding common stock held by non-affiliates is approximately $21,189,735 based on reported share prices. The funds raised from the offering are intended primarily for research, development, and general corporate purposes, as outlined in the document. This strategy reflects Aptevo's position as a clinical-stage biotechnology company focused on immunotherapy for cancer treatment, emphasizing its innovative approaches and the risks associated with investing in their stock.

Form Type: 424B4

Filing Date: 2025-04-22

Corporate Action: Ipo

Type: New

Accession Number: 000095017025056475

Filing Summary: Aptevo Therapeutics Inc. is offering 2,324,000 shares of its common stock, priced at $0.862 per share, under a registered direct offering as detailed in the prospectus supplement filed on April 21, 2025. The offering, arranged by Roth Capital Partners, LLC as the exclusive placement agent, will result in gross proceeds of approximately $2,003,288 before expenses, with an expected closing date of April 22, 2025. The offering represents less than one-third of the aggregate market value of Aptevo's outstanding common stock held by non-affiliates, adhering to SEC guidelines. Aptevo specializes in developing immunotherapy candidates for cancer treatment, boasting innovative technologies and promising clinical candidates like mipletamig for acute myelogenous leukemia and ALG.APV-527 for solid tumors. The prospectus also emphasizes the risks involved in investing in common stock, including market conditions and corporate performance. Additionally, the document highlights the company's strategic growth plans and the intended use of proceeds, primarily for research and development activities.

Form Type: 424B4

Filing Date: 2025-04-04

Corporate Action: Ipo

Type: New

Accession Number: 000095017025050924

Filing Summary: Aptevo Therapeutics Inc. is conducting a registered direct offering of 1,764,710 shares of common stock at a price of $1.19 per share, along with two Common Warrants for each share purchased in a concurrent private placement. Each Common Warrant allows the holder to purchase one additional share of common stock at the same price, which requires stockholder approval for exercise. The offering is projected to generate approximately $1.9 million in net proceeds, intended for working capital and further development of product candidates. The Common Warrants have an initial exercise price of $1.19 and expire five years after stockholder approval. The company has engaged Roth Capital Partners, LLC as the exclusive placement agent for this offering. As of April 3, 2025, Aptevo’s common stock is listed on the Nasdaq Capital Market under the symbol 'APVO' with a reported closing price of $1.99 per share on that date.

Form Type: S-1/A

Filing Date: 2025-04-01

Corporate Action: Ipo

Type: Update

Accession Number: 000095017025048016

Filing Summary: Aptevo Therapeutics Inc. has filed an amendment to its S-1 registration statement, proposing a public offering of up to 15,086,207 shares of common stock, accompanied by pre-funded and common warrants. These securities are aimed at facilitating growth and funding for the company’s drug development pipeline. The registration also includes significant details regarding terms like the exercise prices of warrants, adjustments based on stockholder approval, and restrictions on further issuances for a specified period. The filing emphasizes the company's focus on developing novel immunotherapy candidates, with ongoing clinical trials aimed at treating various types of cancer. Aptevo is also navigating regulatory challenges and market requirements to ensure compliance and successful funding.

Form Type: S-1/A

Filing Date: 2025-03-27

Corporate Action: Ipo

Type: New

Accession Number: 000095017025045728

Filing Summary: On March 27, 2025, Aptevo Therapeutics Inc. filed an amendment (S-1/A) to its registration statement under the Securities Act of 1933 to offer up to 12,987,013 shares of common stock and various warrants including Series A and Series B warrants alongside pre-funded warrants. The company aims to proceed with a public offering as soon as practicable after the registration statement becomes effective. The shares offered are at an assumed public offering price of $1.54 per share. Additionally, the company has stated that proceeds from this offering will support their clinical development programs, including lead candidates mipletamig and ALG.APV-527, aimed at treating different forms of cancer. Notably, the filing details mechanisms for serious investor participation, while also discussing the exercise pricing and the conditions surrounding investor approvals required for warrant exercises. Aptevo aims to leverage their proprietary platform technologies to develop innovative immunotherapies to address challenging cancer types while planning to navigate the risks associated with their operations and funding requirements. The offering is intended to be completed by May 15, 2025, unless terminated earlier. SEC has not yet approved this offering, indicating regulatory consideration is still pending.

Form Type: S-1/A

Filing Date: 2025-03-27

Corporate Action: Ipo

Type: New

Accession Number: 000095017025046199

Filing Summary: Aptevo Therapeutics Inc. is filing an amendment to its registration statement for a public offering of securities, specifically aiming to sell up to 12,987,013 shares of common stock along with pre-funded warrants and Series A and B Warrants. These warrants entitle purchasers to purchase additional shares of common stock. The offering is structured to include a reasonable best efforts public offering at an assumed price of $1.54 per share. The series of warrants have specific terms regarding exercise pricing and stockholder approvals. Notably, holders of Series B Warrants have the option of a zero exercise price, which could result in the issuance of a substantial number of additional shares. The document outlines the risks associated with the investment, details about the underwriting and placement agent, and other regulatory notices. The expected termination date for the offering, barring any termination by the issuer, is noted as May 15, 2025. Additionally, the company's common stock is currently listed on the Nasdaq Capital Market under the symbol 'APVO.'

Form Type: S-1

Filing Date: 2025-03-03

Corporate Action: Ipo

Type: New

Accession Number: 000095017025030286

Filing Summary: Aptevo Therapeutics Inc. is filing a registration statement under the Securities Act of 1933. The company aims to conduct a public offering of up to 1,557,632 shares of common stock, along with various warrants. The offering includes pre-funded warrants for those whose purchases may cause them to exceed 4.99% ownership of the company. The offering is designed to raise funds for clinical development of Aptevo's cancer therapies, including mipletamig and ALG.APV-527, which target different cancer types. The company emphasizes its innovative ADAPTIR® platforms for engineering therapeutic candidates and highlights favorable preliminary clinical results from ongoing trials, stating a 100% complete remission rate for the lead candidate in a recent cohort. The document outlines terms of the offering, risks associated with the investment, and the company’s strategy to collaborate with other entities to support its development. Additionally, the offering will terminate by April 15, 2025, unless otherwise decided by the company.